NCT07481890 Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients.
| NCT ID | NCT07481890 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lega Cancro Ticino |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2026-03-27 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 46 participants in total. It began in 2026-03-27 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The incidence of adverse childhood experiences (ACEs) is significantly elevated in patients affected by organic diseases (Riedl, 2020). Adverse childhood experiences include life events such as physical, emotional, and sexual abuse; exposure to domestic violence; abandonment; and physical and emotional neglect occurring during early stages of life. One of the primary and most extensively studied mechanisms through which ACEs appear to influence the development of organic diseases across the lifespan is dysregulation of cortisol levels, which acts as a key mediator of increased macro- and microcellular inflammatory processes. In rhis context, it is important to integrate the standard triage and psychological distress screening interventions routinely provided by psychologists working in clinical liaison psychology services with specialized, evidence-based psychotherapeutic treatments delivered by appropriately trained professionals. Among the range of evidence-based psychotherapies currently available, Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy-hereafter referred to as EMDR-was recognized by the World Health Organization (WHO) in 2013 and reaffirmed in 2024 as one of the treatments of choice for trauma and the psychophysiological consequences of adverse events. Since 2015, Manuela Spadoni has systematized the empirical evidence, theoretical concepts, the parts model, and the operational tools of the additional EMDR procedures introduced by Jim Knipe beginning in 2001 into a structured psychotherapeutic approach known as the EMDR Toolbox method. This method appears to be particularly well suited for treating individuals whose clinical history is characterized by multiple adverse experiences. The present randomized trial aims to evaluate the feasibility and efficacy of the EMDR Toolbox Method (ETM) in patients diagnosed with oncological disease.
Eligibility Criteria
Inclusion Criteria: * Clinical stage of the tumor: Stage I, II (TNM classification) * Age ≥ 18 years \<=65 * Conditions enabling correct implementation of the proposed program (ability to complete questionnaires) * Written informed consent Exclusion Criteria: * Psychiatric or other disorders that may impair the ability to provide informed consent.
Contact & Investigator
Paola Arnaboldi
PRINCIPAL INVESTIGATOR
Lega Cancro Ticino
Frequently Asked Questions
Who can join the NCT07481890 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07481890 currently recruiting?
Yes, NCT07481890 is actively recruiting participants. Contact the research team at paola.arnaboldi@legacancro-ti.ch for enrollment information.
Where is the NCT07481890 trial being conducted?
This trial is being conducted at Bellinzona, Switzerland, Bellinzona, Switzerland.
Who is sponsoring the NCT07481890 clinical trial?
NCT07481890 is sponsored by Lega Cancro Ticino. The principal investigator is Paola Arnaboldi at Lega Cancro Ticino. The trial plans to enroll 46 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.